| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 78.57% | Guggenheim | $30 → $25 | Maintains | Buy |
| 11/08/2023 | 121.43% | Raymond James | $40 → $31 | Maintains | Strong Buy |
| 11/01/2023 | 14.29% | B of A Securities | $35 → $16 | Downgrades | Buy → Neutral |
| 10/13/2023 | 28.57% | Stifel | → $18 | Initiates Coverage On | → Hold |
| 09/27/2023 | 92.86% | Morgan Stanley | → $27 | Assumes | → Overweight |
| 09/15/2023 | 114.29% | Guggenheim | $32 → $30 | Maintains | Buy |
| 08/16/2023 | 128.57% | Guggenheim | $34 → $32 | Maintains | Buy |
| 08/04/2023 | 128.57% | Morgan Stanley | $32 → $32 | Reiterates | Overweight → Overweight |
| 06/28/2023 | 128.57% | Roth MKM | $40 → $32 | Maintains | Buy |
| 06/28/2023 | 64.29% | Baird | $36 → $23 | Maintains | Neutral |
| 06/27/2023 | 64.29% | Baird | $36 → $23 | Maintains | Neutral |
| 06/08/2023 | 185.71% | Raymond James | $40 → $40 | Maintains | Strong Buy |
| 05/08/2023 | 142.86% | Guggenheim | $31 → $34 | Maintains | Buy |
| 05/08/2023 | 128.57% | Morgan Stanley | $30 → $32 | Maintains | Overweight |
| 05/08/2023 | 178.57% | Citigroup | $32 → $39 | Maintains | Buy |
| 05/05/2023 | 185.71% | Raymond James | $32 → $40 | Maintains | Strong Buy |
| 05/05/2023 | 200% | Piper Sandler | $36 → $42 | Maintains | Overweight |
| 04/26/2023 | 185.71% | B. Riley Securities | $32 → $40 | Maintains | Buy |
| 04/10/2023 | 171.43% | Lake Street | → $38 | Initiates Coverage On | → Buy |
| 04/05/2023 | 142.86% | Baird | → $34 | Downgrades | Outperform → Hold Neutral |
| 03/13/2023 | 121.43% | Guggenheim | $29 → $31 | Maintains | Buy |
| 03/06/2023 | 128.57% | Citigroup | $31 → $32 | Maintains | Buy |
| 03/03/2023 | 114.29% | Morgan Stanley | $28 → $30 | Maintains | Overweight |
| 03/03/2023 | 128.57% | Raymond James | $30 → $32 | Maintains | Strong Buy |
| 02/15/2023 | 121.43% | Citigroup | $29 → $31 | Maintains | Buy |
| 01/31/2023 | 100% | Morgan Stanley | $26 → $28 | Maintains | Overweight |
| 01/13/2023 | 128.57% | B. Riley Securities | $30 → $32 | Maintains | Buy |
| 01/10/2023 | 128.57% | Baird | $30 → $32 | Maintains | Outperform |
| 12/06/2022 | 107.14% | Citigroup | → $29 | Initiates Coverage On | → Buy |
| 11/11/2022 | 85.71% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 11/11/2022 | 114.29% | B. Riley Securities | $29 → $30 | Maintains | Buy |
| 11/11/2022 | 114.29% | Raymond James | $29 → $30 | Maintains | Strong Buy |
| 11/11/2022 | 157.14% | Piper Sandler | $34 → $36 | Maintains | Overweight |
| 09/15/2022 | 107.14% | B. Riley Securities | → $29 | Initiates Coverage On | → Buy |
| 08/12/2022 | 107.14% | Raymond James | $27 → $29 | Maintains | Strong Buy |
| 03/15/2022 | 142.86% | Evercore ISI Group | → $34 | Initiates Coverage On | → Outperform |
| 03/04/2022 | 92.86% | Raymond James | $28 → $27 | Maintains | Strong Buy |
| 11/16/2021 | 107.14% | Roth Capital | → $29 | Initiates Coverage On | → Buy |
| 11/12/2021 | 100% | Raymond James | $14 → $28 | Maintains | Strong Buy |
| 09/22/2021 | 0% | Raymond James | → $14 | Upgrades | Market Perform → Strong Buy |
| 08/17/2021 | 28.57% | B of A Securities | → $18 | Initiates Coverage On | → Buy |
| 08/17/2021 | 114.29% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 08/17/2021 | 21.43% | Morgan Stanley | → $17 | Initiates Coverage On | → Overweight |
| 08/17/2021 | 14.29% | Baird | → $16 | Initiates Coverage On | → Outperform |
| 08/17/2021 | 3.57% | Citigroup | → $14.5 | Initiates Coverage On | → Buy |
| 08/17/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 08/17/2021 | 28.57% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 08/17/2021 | 42.86% | Piper Sandler | → $20 | Initiates Coverage On | → Overweight |
What is the target price for Xponential Fitness (XPOF)?
The latest price target for Xponential Fitness (NYSE: XPOF) was reported by Guggenheim on November 15, 2023. The analyst firm set a price target for $25.00 expecting XPOF to rise to within 12 months (a possible 78.57% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xponential Fitness (XPOF)?
The latest analyst rating for Xponential Fitness (NYSE: XPOF) was provided by Guggenheim, and Xponential Fitness maintained their buy rating.
When is the next analyst rating going to be posted or updated for Xponential Fitness (XPOF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xponential Fitness, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xponential Fitness was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Xponential Fitness (XPOF) correct?
While ratings are subjective and will change, the latest Xponential Fitness (XPOF) rating was a maintained with a price target of $30.00 to $25.00. The current price Xponential Fitness (XPOF) is trading at is $14.00, which is out of the analyst's predicted range.